Pharmaceuticals Analysts discuss the implications of Merck’s Sotatercept’s Phase III STELLAR data on treatment of Pulmonary Arterial Hypertension (PAH) on an Analyst/Industry conference call to be held on March 9.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- Merck to hold a virtual investor event
- Illumina and Myriad Genetics partner for HRD testing in the U.S.
- AstraZeneca says FDA to convene AdCom meeting on sNDA for Lynparza in mCRPC
- BeyondSpring enrolls first patient in study of Plinabulin, Keytruda, Docetaxel
- Merck says Phase 3 KEYNOTE-671 trial met one of dual primary endpoints